American Biogenetic Sciences' (ABS) and Roche collaborate on thrombus precursor protein (TpP) test
This article was originally published in Clinica
Executive Summary
Roche is to collaborate in the development of American Biogenetic Sciences' (ABS) active thrombosis test (see Clinica No 674, p 15). The two companies will adapt the thrombus precursor protein (TpP) test to a latex agglutination format for use with Roche's automated diagnostics systems. ABS will manufacture kits in exchange for a percentage of selling price plus a royalty. The test will also be sold to other companies on a profit-sharing basis.